Status:
COMPLETED
Peri-luminal COROnary CTa AI-driven radiOMICS to Identify Vulnerable Patients (CORO-CTAIOMICS)
Lead Sponsor:
IRCCS San Raffaele
Collaborating Sponsors:
Ministry of Health, Italy
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Brief Summary
CAD is a leading cause of mortality in Europe. cCTA is recommended to rule out obstructive CAD, but, in most patients, it shows non-obstructive CAD. The management of these patients is unclear due to ...
Detailed Description
Background and rationale In the last years, cCTA has become a pivotal diagnostic tool in the setting of suspected CAD. The latest ESC guidelines recommend cCTA as the first line diagnostic test for p...
Eligibility Criteria
Inclusion
- Patients with CT performed for CAD assessment between 2017 and 2019.
- Follow-up duration of at least 4 years.
Exclusion
- Refusal to participate in the study
- Age \<18 years old
- History of previous coronary revascularization
- Presence of other cardiovascular comorbidities (e.g. inflammatory cardiomyopathy, valvular cardiomyopathy, idiopathic dilated cardiomyopathy, infiltrative cardiomyopathy)
Key Trial Info
Start Date :
July 31 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 24 2024
Estimated Enrollment :
2190 Patients enrolled
Trial Details
Trial ID
NCT06029777
Start Date
July 31 2023
End Date
September 24 2024
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS San Raffaele
Milan, Italy, 20132